Disease · MONDO_0006687
burning mouth syndrome
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. burning mouth syndrome. Diseases, record MONDO_0006687. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0006687
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
Drugs31
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| CLONAZEPAM | CHEMBL452 | Small molecule | Phase 3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| CITALOPRAM | CHEMBL549 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| DULOXETINE | CHEMBL1175 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ESCITALOPRAM | CHEMBL1508 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| FERRIC CARBOXYMALTOSE | CHEMBL2108597 | Phase 3 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets | |
| FERRIC OXYHYDROXIDE | CHEMBL4802224 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
| FERROUS SULFATE | CHEMBL1200830 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
| FOLIC ACID | CHEMBL1622 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| IRON ISOMALTOSIDE 1000 | CHEMBL4298046 | Phase 3 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets | |
| PAROXETINE | CHEMBL490 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 31
See all 31 drugsTargets60
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| SLC6A4 | Sodium-dependent serotonin transporter | 7 | Serotonin transporter inhibitor | Phase 3 | https://conductscience.org/library/genes/6532 | Drugs and targets |
| GABRA1 | GABA-A receptor; anion channel | 2 | GABA-A receptor; anion channel positive allosteric modulator | Phase 3 | https://conductscience.org/library/genes/2554 | Drugs and targets |
| GABRA2 | GABA-A receptor; anion channel | 2 | GABA-A receptor; anion channel positive allosteric modulator | Phase 3 | https://conductscience.org/library/genes/2555 | Drugs and targets |
| GABRA3 | GABA-A receptor; anion channel | 2 | GABA-A receptor; anion channel positive allosteric modulator | Phase 3 | https://conductscience.org/library/genes/2556 | Drugs and targets |
| GABRA4 | GABA-A receptor; anion channel | 2 | GABA-A receptor; anion channel positive allosteric modulator | Phase 3 | https://conductscience.org/library/genes/2557 | Drugs and targets |
| GABRA5 | GABA-A receptor; anion channel | 2 | GABA-A receptor; anion channel positive allosteric modulator | Phase 3 | https://conductscience.org/library/genes/2558 | Drugs and targets |
| GABRA6 | GABA-A receptor; anion channel | 2 | GABA-A receptor; anion channel positive allosteric modulator | Phase 3 | https://conductscience.org/library/genes/2559 | Drugs and targets |
| GABRB1 | GABA-A receptor; anion channel | 2 | GABA-A receptor; anion channel positive allosteric modulator | Phase 3 | https://conductscience.org/library/genes/2560 | Drugs and targets |
| GABRB2 | GABA-A receptor; anion channel | 2 | GABA-A receptor; anion channel positive allosteric modulator | Phase 3 | https://conductscience.org/library/genes/2561 | Drugs and targets |
| GABRB3 | GABA-A receptor; anion channel | 2 | GABA-A receptor; anion channel positive allosteric modulator | Phase 3 | https://conductscience.org/library/genes/2562 | Drugs and targets |
1 to 10 of 60
See all 60 targetsTrials17
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00716807 | Efficacy of Nalbuphine and Naloxone Administered as Nose Sprays in the Treatment of Orofacial Pain | Not applicable | 46 | 2013-10-22 | Temporomandibular Joint Dysfunction Syndrome, Burning Mouth Syndrome | NALBUPHINE, NALOXONE | Its record names the disease | ClinicalTrials.gov |
| NCT04481841 | Head Yuanshi Dian Therapy in Burning Mouth Syndrome | Early phase 1 | 290 | Burning Mouth Syndrome, Oral Mucosa Disease | ORYZANOL, RIBOFLAVIN, VITAMIN E | Its record names the disease | ClinicalTrials.gov | |
| NCT06025474 | Comparison of Vortioxetine Versus Other Antidepressants With Pregabalin Augmentation in Burning Mouth Syndrome | Phase 3 | 203 | Burning Mouth Syndrome | CITALOPRAM, DULOXETINE, ESCITALOPRAM, PAROXETINE, PREGABALIN, SERTRALINE, VORTIOXETINE | Its record names the disease | ClinicalTrials.gov | |
| NCT06195137 | Caffeine vs. ALA in BMS Treatment. (BMS: Burning Mouth Syndrome. ALA: Alpha-Lipoic Acid.) | Not applicable | 130 | Caffeine, Burning Mouth Syndrome | CAFFEINE, LIPOIC ACID, ALPHA | Its record names the disease | ClinicalTrials.gov | |
| NCT03788733 | The Efficacy of Melatonin in the Burning Mouth Syndrome | Not applicable | 80 | Sleep Disorders, Circadian Rhythm | MELATONIN | Its record names the disease | ClinicalTrials.gov | |
| NCT04189367 | Treatment of Burning Mouth Syndrome With Integration of Traditional Chinese Medicine and Western Medicine | Phase 3 | 80 | Burning Mouth Syndrome | CLONAZEPAM, FOLIC ACID, VITAMIN B12 | Its record names the disease | ClinicalTrials.gov | |
| NCT07381361 | Photobiomodulation Therapy vs. Alpha-Lipoic Acid in Burning Mouth Syndrome Treatment | Not applicable | 60 | Burning Mouth Syndrome, Low Level Laser Therapy | LIPOIC ACID, ALPHA | Its record names the disease | ClinicalTrials.gov | |
| NCT04884503 | Evaluation of the Effectiveness of the Selected Method of Treatment of Primary Burning Mouth Syndrome | Phase 2 | 58 | Burning Mouth Syndrome, Glossodynia | CLONAZEPAM | Its record names the disease | ClinicalTrials.gov | |
| NCT05059418 | Burning Mouth Syndrome - New Diagnostic Criteria and Treatment | Not applicable | 40 | Burning Mouth Syndrome | CAPSAICIN, CLONAZEPAM | Its record names the disease | ClinicalTrials.gov | |
| NCT05872789 | Impact of Diazepam 1% Oral Gel Efficacy in Burning Mouth Syndrome | Not applicable | 40 | Burning Mouth Syndrome | DIAZEPAM | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 17
See all 17 trialsComparisons in its trials0
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
None in this release.
Papers from its trials46
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0006687
GET https://conductscience.org/api/diseases/v1/MONDO_0006687/drugs?page=2